Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants
Quotient Limited Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of Financials
• Pre-announces FY 2022 revenue of $38.5 million
• Secured $1.4 million of orders in Q1 FY23 for recently CE Marked Extended IH MosaiQ Solution
• $83.2 million in cash and investments as of March 31, 2022
• Secured $1.4 million of orders in Q1 FY23 for recently CE Marked Extended IH MosaiQ Solution
• $83.2 million in cash and investments as of March 31, 2022
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
- Partnership brings together novel technology and clinical applications expertise to produce automated, multiplexed solutions for advancing autoimmune diagnostics
- Expands access to $2 billion autoimmune IVD specialty market with MosaiQ
- Targeted market introduction…
- Expands access to $2 billion autoimmune IVD specialty market with MosaiQ
- Targeted market introduction…
Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
Virtual event on Monday, May 23rd at 11:00 AM ET
The webinar will provide a detailed discussion on the current landscape and unmet needs within blood grouping and donor disease screening
The webinar will provide a detailed discussion on the current landscape and unmet needs within blood grouping and donor disease screening